News

The FDA has approved the co-packaging of oral medication ribociclib and letrozole, used to treat HR-positive, HER2-negative advanced breast cancer in postmenopausal women.

The FDA has granted accelerated approval to avelumab (Bavencio) for the treatment of patients with locally advanced or metastatic urothelial carcinoma.

At the 2017 ONS Annual Congress, nurses from John Hopkins Sidney Kimmel Cancer Center reported on their study involving vincristine infused via minibag infusions.

The revised American Health Care Act has passed through the House of Representatives.

At the 2017 Community Oncology Alliance annual conference, panelists discussed techniques to encourage improved adherence in patients on oral oncology medication.

ASCO has updated their guidance on the use of second-line hormonal therapy for chemotherapy-naive patients with castration-resistant prostrate cancer (CRPC).

A recent trial is evaluating a new drug to treat cachexia, testing its efficacy in dogs currently.

The FDA has granted accelerated approval for the PD-L1 inhibitor durvalumab for the treatment of locally advanced or metastatic urothelial carcinoma.

The FDA has granted accelerated approval to brigatinib for patients with metastatic ALK-positive non-small cell lung cancer (NSCLC) resistant to prior crizotinib (Xalkori).

A recent study indicates that the use of bilateral mastectomy to treat women with ductal carcinoma in situ is unnecessary.

The FDA has approved midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukemia.

A recent study has found correlations between common comorbidities (hypertension, heart disease, diabetes, etc) and ovarian cancer.

The FDA has approved regorafenib as a second-line treatment for patients with unresectable hepatocellular carcinoma, who had previously received sorafenib.

A recent study evaluated the effect of red light on hair growth in women with breast cancer.

Second primary cancers that occur in pediatric, adolescent and young adult (AYA) patients are deadlier than those that occur in older patients.

The FDA issued 14 warning letters and 4 online adviseries to a number of companies selling products which claim to prevent, diagnose, treat, mitigate or cure cancer without FDA approval.

While patients with stage III or IV melanoma who received a higher dose of ipilimumab did live longer than those on a lower dose, there was also greater toxicity.

For patients with hepatocellular carcinoma (HCC) who have progressed on sorafenib, regorafenib has shown to be an effective second-line treatment. The FDA has granted the agent a priority review

Steve Pake, a testicular cancer survivors gives some insight as April is testicular cancer awareness month.

For patients receiving oral chemotherapy, satisfaction with communication may enhance adherence.

For BRCA1/2 and other genes, it is important that practitioners begin testing for heriditary genes for ovarian cancers.

The UK Myeloma Forum and the British Society for Haematology collaborated to create a comprehensive, multidisciplinary guideline document for the screening, management, and long-term care of patients with myeloma.

The Paxman Scalp Cooling System has been granted FDA clearance to reduce hait loss in patients with breast cancer recieving chemotherapy.

New modalities of treatments for patients with Ewing sarcoma have expanded overall survival. However, there are few studies done on the long-term quality of life issues these patients may experience.

Several patient-related risk factors for chemotherapy-induced nausea and vomiting (CINV) have been identified and compiled into a CINV prediction tool.

With more patients diagnosed with breast cancer looking to contralateral prophylactic mastectomy, it is important that surgeons discuss this procedure in-depth so patients can better understand.

The Food and Drug Administration (FDA) granted an accelerated approval to atezolizumab (Tecentriq) to be used as a frontline treatment for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma (mUC).